Bionovo Enrolls First Patient in Phase I/II Trial
Posted on: Wednesday, 18 April 2007, 15:00 CDT
Bionovo has initiated a phase I/II trial of its drug candidate for the treatment of women with advanced breast cancer.
The aims of the current phase I/II trial are to determine the maximum tolerated dose of the drug candidate BZL101 and tumor response in women with late stage breast cancer. The trial will enroll 80 volunteers who have advanced measurable breast cancer and have had no more than two prior third line cytotoxic treatments.
BZL101 is an oral drug designed to induce cancer cell apoptosis, or cell death, while leaving normal cells unaffected. Results from the company's initial FDA-approved phase I clinical trial showed BZL101 was safe in a cohort of women with advanced breast cancer.
"We are excited to bring our second Bionovo drug candidate into phase II clinical testing to further advance our pipeline and to find safer, less toxic therapeutic treatment options for women with advanced breast cancer," stated Isaac Cohen, CEO and president of Bionovo.
Source: Datamonitor
Related Articles
- New Survey Underscores Importance of Psychosocial and Educational Needs Among Women With Advanced Breast Cancer
- Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
- Myriad Brain Cancer Drug Advances to Phase II
- AstraZeneca Lung Cancer Drug Advances to Phase III
- Understand Current Epidemiological Trends in Gynecological Cancer and Ongoing Treatment Controversies Inside 2006 Report Gynecological Cancers - Niche Opportunities in Advanced Disease
- Cardium Heart Drug Advances to Phase III
- Ligand Platelet Drug Advances to Phase I
- Breast Cancer Accounts for Almost a Third of Cancers in Women
- Ariad Initiates Trial of Anticancer Candidate
- Phase III Study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19
 |
 |
User Comments (0)
RSS Feeds